Literature DB >> 24243286

Treatment failure in patients with chronic Blastocystis infection.

Tamalee Roberts1,2, John Ellis1, John Harkness2, Deborah Marriott2, Damien Stark2.   

Abstract

This article reports long-term infection and treatment failure in 18 symptomatic individuals infected with Blastocystis spp. Patients were initially treated with either metronidazole, iodoquinol or triple combination therapy consisting of nitazoxanide, furazolidone and secnidazole. Following treatment, resolution of clinical symptoms did not occur and follow-up testing revealed ongoing infection with the same subtype. Patients then underwent secondary treatment with a variety of antimicrobial agents but remained symptomatic with Blastocystis spp. still present in faeces. Sequencing of the SSU rDNA was completed on all isolates and four subtypes were identified in this group: ST1, ST3, ST4 and ST5. This study highlights the lack of efficacy of several commonly used antimicrobial regimens in the treatment of Blastocystis and the chronic nature of some infections. It also demonstrates the need for further research into treatment options for Blastocystis infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24243286     DOI: 10.1099/jmm.0.065508-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  15 in total

Review 1.  Understanding the contribution of environmental factors in the spread of antimicrobial resistance.

Authors:  Stephanie Fletcher
Journal:  Environ Health Prev Med       Date:  2015-04-29       Impact factor: 3.674

Review 2.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

3.  Evaluation of the effect of 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol in comparison with metronidazole in an in vitro culture of Blastocystis in samples of patients with irritable bowel syndrome.

Authors:  L García-Flores; J G Santillán-Benítez; E Cuevas-Yáñez; P Caballero-Vásquez; S Zamudio-Chávez; E Morales-Ávila
Journal:  J Parasit Dis       Date:  2019-05-02

4.  In Vitro Antimicrobial Susceptibility Patterns of Blastocystis.

Authors:  Tamalee Roberts; Stephen Bush; John Ellis; John Harkness; Damien Stark
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

5.  Blastocystis and Clostridioides difficile: Evidence for a Synergistic Role in Colonization Among IBD Patients with Emphasis on Ulcerative Colitis.

Authors:  Masoumeh Azimirad; Sara Mohammad Ali Gol; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Shabnam Shahrokh; Hedieh Balaii; Amir Sadeghi; Mohammad Reza Zali
Journal:  Turk J Gastroenterol       Date:  2021-06       Impact factor: 1.852

6.  Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of Blastocystis Subtype 1, 4, and 7 Isolates.

Authors:  John Anthony Yason; Kristine Anne Ru Ping Koh; Kevin Shyong Wei Tan
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patients.

Authors:  Robyn Nagel; Helle Bielefeldt-Ohmann; Rebecca Traub
Journal:  Gut Pathog       Date:  2014-08-20       Impact factor: 4.181

8.  Epidemiology and geographical distribution of enteric protozoan infections in sydney, australia.

Authors:  Stephanie Fletcher; Graziella Caprarelli; Juan Merif; David Andresen; Sebastian Van Hal; Damien Stark; John Ellis
Journal:  J Public Health Res       Date:  2014-08-25

Review 9.  Update on the pathogenic potential and treatment options for Blastocystis sp.

Authors:  Tamalee Roberts; Damien Stark; John Harkness; John Ellis
Journal:  Gut Pathog       Date:  2014-05-28       Impact factor: 4.181

10.  HIGH PREVALENCE OF Blastocystis spp. INFECTION IN CHILDREN AND STAFF MEMBERS ATTENDING PUBLIC URBAN SCHOOLS IN SÃO PAULO STATE, BRAZIL.

Authors:  Mayra Frozoni Rebolla; Eliete Maria Silva; Jancarlo Ferreira Gomes; Alexandre Xavier Falcão; Maria Vicentina Frozoni Rebolla; Regina Maura Bueno Franco
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-04-08       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.